# Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in **Clinical Trials**  
**News**  
May 02, 2024

[Clinical Trials](/content/us/science-innovation/human-health-innovation/clinical-studies/clinical-trials "Clinical Trials"/index.html)

# Clinical Trials

Find out more on why Boehringer Ingelheim's range of **clinical trials** are an essential aspect of new medicine development.  
**Science & Innovation**  
**Stories**

[Confronting health disparities in clinical trials](/content/us/human-health/cancer/confronting-health-disparities-clinical-trials "Confronting health disparities in clinical trials"/index.html)

# Confronting health disparities in clinical trials

As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for **clinical cancer trials**.  
**Human Health**  
**Stories**

[Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers](/content/us/media/press-releases/boehringer-ingelheim-advances-novel-bi-specific-trailr2-cdh17-antibody-phase-1-clinical-trial "Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers"/index.html)

# Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

BI announces the advancement of the tetravalent therapeutic antibody, BI 905711, to its first-in-human **clinical trial** for patients with advanced GI cancers.  
**News**  
September 10, 2020

[Clinical Studies](/content/us/science-innovation/human-health-innovation/clinical-studies "Clinical Studies"/index.html)

# Clinical Studies

BI's **clinical trials** are an essential part of the development of new medicines, being the translation of our expertise into breakthrough therapies.  
**Science & Innovation**  
**Other**

[Expanded Access Programs](/content/us/science-innovation/human-health-innovation/clinical-studies/expanded-access-programs "Expanded Access Programs"/index.html)

# Expanded Access Programs

Expanded Access Programs  
**Science & Innovation**  
**Other**

[Clinical trials deliver medical breakthroughs – but how do they happen?](/content/us/careers/explore-our-company/clinical-trials-deliver-medical-breakthroughs-how-do-they-happen "Clinical trials deliver medical breakthroughs – but how do they happen?"/index.html)

# Clinical trials deliver medical breakthroughs – but how do they happen?

**Clinical trials** deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.  
**Careers**  
**Stories**

[U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes](/content/us/media/press-releases/us-fda-approves-synjardy-empagliflozin-metformin-hydrochloride-tablets-adults-type-2-diabetes "U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride/index.html) tablets for adults with type 2 diabetes")

# U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Read more about the FDA approval of SYNJARDY, based on multiple **clinical trials** proving the reductions of blood sugar levels in adults with T2D.  
**News**  
August 27, 2015

[First Trials of Empagliflozin in Chronic Heart Failure \| Boehringer Ingelheim US](/content/us/media/press-releases/first-trials-empagliflozin-chronic-heart-failure-boehringer-ingelheim-us "First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US"/index.html)

# First Trials of Empagliflozin in Chronic Heart Failure \| Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) **clinical trial** program was initiated.  
**News**  
March 17, 2017

[Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction](/content/us/media/press-releases/boehringer-ingelheim-and-lilly-collaborate-duke-clinical-research-institute-pragmatic-trial "Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction"/index.html)

# Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

Read more on how the trial is part of the EMPOWER **clinical trial** program, the broadest and most comprehensive of any SGLT2 inhibitor.  
**News**  
May 26, 2020

# References